iBio (IBIO) Competitors

CARGO Therapeutics (NASDAQ:CRGX) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.

Do analysts rate CRGX or IBIO?

CARGO Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 258.85%. iBio has a consensus target price of $4.30, indicating a potential downside of 2.49%. Given CARGO Therapeutics' higher possible upside, equities research analysts clearly believe CARGO Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CARGO Therapeutics	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
iBio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is CRGX or IBIO more profitable?

CARGO Therapeutics' return on equity of -38.16% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CARGO Therapeutics	N/A	-38.16%	-33.94%
iBio	N/A	-73.15%	-45.51%

Does the MarketBeat Community believe in CRGX or IBIO?

CARGO Therapeutics received 11 more outperform votes than iBio when rated by MarketBeat users. Likewise, 66.67% of users gave CARGO Therapeutics an outperform vote while only 37.50% of users gave iBio an outperform vote.

Company	Underperform	Outperform
CARGO Therapeutics	Outperform Votes 14 66.67%	Underperform Votes 7 33.33%
iBio	Outperform Votes 3 37.50%	Underperform Votes 5 62.50%

Do institutionals and insiders believe in CRGX or IBIO?

93.2% of CARGO Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.4% of CARGO Therapeutics shares are held by insiders. Comparatively, 0.6% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, CRGX or IBIO?

iBio has higher revenue and earnings than CARGO Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CARGO Therapeutics	N/A	N/A	-$98.15M	-$3.72	-1.12
iBio	$375K	116.13	-$24.91M	N/A	N/A

Does the media prefer CRGX or IBIO?

In the previous week, CARGO Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 4 mentions for CARGO Therapeutics and 1 mentions for iBio. iBio's average media sentiment score of 0.00 beat CARGO Therapeutics' score of -0.07 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CARGO Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, CRGX or IBIO?

CARGO Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, iBio has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Summary

CARGO Therapeutics beats iBio on 9 of the 14 factors compared between the two stocks.